Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Overall Financial Health and Key Highlights
ABBV logo

AbbVie Revenues Surge 12.4% to $15 Billion as Skyrizi and Rinvoq Offset Humira Declines

ABBV8-KFiling Date: 4/29/2026
AbbVie Inc.
Description

What this story covers

AbbVie’s Q1 2026 results show a 12.4% revenue jump to $15 billion, driven by explosive growth in Skyrizi and Neuroscience. Despite Humira’s decline and heavy R&D spending, the company raised its full-year earnings guidance, signaling a successful strategic pivot.

Story snapshot

CompanyAbbVie Inc.
TickerABBV
VariantStandard detailed
Duration5:01
Filing type8-K
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0001551152-26-000013
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing8-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in